Detail akcie PAION Br online

Business Summary: Paion AG is a Germany-based biopharmaceutical company. The Company's main product is remimazolam, an intravenous ultra-short-acting benzodiazepine sedative and anesthetic. In the human body, remimazolam is metabolized to an inactive metabolite by tissue esterase and not metabolized by cytochrome-dependent hepatic pathways. In addition to that, remimazolam, which is in Phase III clinical development, can be reversed with flumazenil to terminate sedation and anesthesia, if necessary. The product can be used for general anesthesia in Europe and procedural sedation in the United States. The Company operates sites in Aachen, Germany, Cambridge, the United Kingdom, and New Jersey, the United States.
Financial Summary: BRIEF: For the six months ended 30 June 2023, Paion AG revenues decreased 73% to EUR6.8M. Net loss applicable to common stockholders totaled EUR9.6M vs. income of EUR9.7M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net loss reflects Financial Expenses increase of 72% to EUR1.7M (expense), Other income (expenses) net increase of 49% to EUR177K (expense).